| European Case Law Identifier: | ECLI:EP:BA:2016:T252412.20160711 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 11 July 2016 | ||||||||
| Case number: | T 2524/12 | ||||||||
| Application number: | 01939145.7 | ||||||||
| IPC class: | A61K 39/395 A61K 31/335 G01N 33/574 A61P 35/00 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy | ||||||||
| Applicant name: | Genentech, Inc. | ||||||||
| Opponent name: | BioGeneriX AG Teva Pharmaceutical Industries Ltd. |
||||||||
| Board: | 3.3.04 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Withdrawal of approval of text on which patent was granted - appeal dismissed | ||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t122524eu1.html
Date retrieved: 17 May 2021